Sage Therapeutics’ (SAGE) “Neutral” Rating Reaffirmed at HC Wainwright

Sage Therapeutics (NASDAQ:SAGE)‘s stock had its “neutral” rating restated by equities research analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $25.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 288.80% from the company’s previous close.

SAGE has been the subject of a number of other research reports. JPMorgan Chase & Co. lowered their target price on Sage Therapeutics from $12.00 to $10.00 and set a “neutral” rating for the company in a research note on Tuesday, August 6th. Truist Financial lowered their price objective on shares of Sage Therapeutics from $18.00 to $13.00 and set a “hold” rating for the company in a research report on Wednesday, August 14th. Robert W. Baird reduced their target price on shares of Sage Therapeutics from $13.00 to $9.00 and set a “neutral” rating on the stock in a research report on Wednesday. The Goldman Sachs Group lowered their price target on shares of Sage Therapeutics from $19.00 to $11.00 and set a “neutral” rating for the company in a report on Friday, July 26th. Finally, Scotiabank dropped their price target on shares of Sage Therapeutics from $19.00 to $17.00 and set a “sector outperform” rating on the stock in a research note on Thursday, July 25th. Two equities research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, Sage Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $15.18.

Sage Therapeutics Stock Down 4.3 %

Shares of SAGE stock opened at $6.43 on Wednesday. Sage Therapeutics has a fifty-two week low of $5.84 and a fifty-two week high of $28.26. The firm’s 50 day moving average price is $7.90 and its two-hundred day moving average price is $11.05. The stock has a market cap of $386.97 million, a price-to-earnings ratio of -0.77 and a beta of 0.91.

Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.68) by ($0.02). Sage Therapeutics had a negative net margin of 458.30% and a negative return on equity of 55.87%. The business had revenue of $8.65 million for the quarter, compared to analyst estimates of $8.85 million. During the same quarter in the previous year, the firm posted ($2.68) EPS. The business’s revenue was up 249.8% compared to the same quarter last year. On average, equities analysts forecast that Sage Therapeutics will post -6.47 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Headlands Technologies LLC lifted its stake in Sage Therapeutics by 245.3% during the second quarter. Headlands Technologies LLC now owns 3,916 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 2,782 shares during the last quarter. Lazard Asset Management LLC bought a new position in shares of Sage Therapeutics in the 1st quarter worth about $127,000. Quest Partners LLC lifted its position in shares of Sage Therapeutics by 14.5% in the 2nd quarter. Quest Partners LLC now owns 11,763 shares of the biopharmaceutical company’s stock worth $128,000 after buying an additional 1,486 shares during the last quarter. Point72 DIFC Ltd acquired a new position in shares of Sage Therapeutics in the 2nd quarter valued at about $153,000. Finally, SG Americas Securities LLC bought a new stake in shares of Sage Therapeutics during the 2nd quarter valued at about $177,000. Institutional investors and hedge funds own 99.22% of the company’s stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.